Interrupting apoptosis in neurodegenerative disease: Potential for effective therapy?

Drug Discovery Today

Volumn 9, Issue 5, 2004, Pages 210-218

  Waldmeier, Peter C ^a   Tatton, William G ^b,c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b RetinaPharma Technologies   (United States)

^c Biodelivery Sciences International   (United States)

Author keywords

Alzheimer; Amyotrophic lateral sclerosis; Apoptosis; Biomarkers; Compounds in development; Development; Drug Discovery; Huntington; Medical need; Mitochondria; Molecular Medicine; Neurodegenerative diseases; Parkinson; Pharmaceutical Science

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; CASPASE; CASPASE INHIBITOR; CEP 1347; CPI 1189; DNA FRAGMENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; MEMANTINE; MINOCYCLINE; PIFITHRIN ALPHA; PROTEIN INHIBITOR; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SULFONAMIDE; TCH 346; UBIDECARENONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AUTOPHAGY; CELL LOSS; CELL REGENERATION; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG ACTIVITY; DRUG RESEARCH; DRUG SCREENING; ENZYME ACTIVATION; EXPERIMENTAL MODEL; HEALTH CARE COST; HUMAN; HUNTINGTON CHOREA; MITOCHONDRION; MOLECULAR DYNAMICS; NERVE CELL; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PREDICTION; REVIEW; RISK; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; DRUG DESIGN; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 1242338861     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)03000-9     Document Type: Review

References (94)

1. Vogels O.J., et al. Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Neurobiol. Aging. 11:1990;3-13.
2. Kruttgen A., et al. Neurotrophins and neurodegenerative diseases: Receptors stuck in traffic? J. Neuropathol. Exp. Neurol. 62:2003;340-350.
3. Cotman C.W., Anderson K.J. Synaptic plasticity and functional stabilization in the hippocampal formation: possible role in Alzheimer's disease. Adv. Neurol. 47:1988;313-335.
4. Tatton W.G., Olanow C.W. Apoptosis in neurodegenerative diseases: the role of mitochondria. Biochim. Biophys. Acta. 1410:1999;195-213.
5. Alexi T., et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases. Prog. Neurobiol. 60:2000;409-470.
6. Schulz J.B., et al. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 267:2000;4904-4911.
7. Cluskey S., Ramsden D.B. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. Mol. Pathol. 54:2001;386-392.
8. Goedert M. The significance of tau and α-synuclein inclusions in neurodegenerative diseases. Curr. Opin. Genet. Dev. 11:2001;343-351.
9. Bazan N.G., et al. Hypoxia signaling to genes: significance in Alzheimer's disease. Mol. Neurobiol. 26:2002;283-298.
10. Butterfield D.A. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic. Res. 36:2002;1307-1313.
11. Miller C.C.J., et al. Axonal transport of neurofilaments in normal and disease states. Cell. Mol. Life Sci. 59:2002;323-330.
12. Thompson A.J., Barrow C.J. Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases. Curr. Med. Chem. 9:2002;1751-1762.
13. Swerdlow R.H. Mitochondrial DNA-related mitochondrial dysfunction in neurodegenerative diseases. Arch. Pathol. Lab. Med. 126:2002;271-280.
14. Hunot S., Hirsch E.C. Neuroinflammatory processes in Parkinson's disease. Ann. Neurol. 53:2003;S49-S60.
15. Li Z., et al. Neurodegeneration: linking ubiquitin/proteasome pathway impairment with inflammation. Int. J. Biochem. Cell Biol. 35:2003;547-552.
16. Pons T., et al. Beta-propellers: associated functions and their role in human diseases. Curr. Med. Chem. 10:2003;505-524.
17. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. New Engl. J. Med. 339:1998;1130-1143.
18. Tolosa E. Advances in the pharmacological management of Parkinson disease. J. Neural Transm. Suppl. 64:2003;65-78.
19. Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs. 15:2001;85-91.
20. Dichter M.A., Locke R.E. Clinical trials in neuroprotection. Expert Opin. Emerg. Drugs. 8:2003;267-271.
21. Jackson M., et al. Therapeutic developments in the treatment of amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs. 11:2002;1343-1364.
22. Jarvis B., Figgitt D.P. Memantine. Drugs Aging. 20:2003;465-476.
23. Shults C.W. Coenzyme Q10 in neurodegenerative diseases. Curr. Med. Chem. 10:2003;1917-1921.
24. Larsen K.E., Sulzer D. Autophagy in neurons: a review. Histol. Histopathol. 17:2002;897-908.
25. Lemasters J.J., et al. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid. Redox Signal. 4:2002;769-781.
26. Tatton W.G., et al. Apoptosis in Parkinson's disease: Signals for neuronal degradation. Ann. Neurol. 53:2003;S61-S72.
27. Waldmeier P.C. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog. Neuropsychopharmacol. Biol. Psychiatry. 27:2003;303-321.
28. Tatton W., et al. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv. Ophthalmol. 48:(Suppl.1):2003;S25-S37.
29. Eldadah B.A., Faden A.I. Caspase pathways, neuronal apoptosis, and CNS injury. J. Neurotrauma. 17:2000;811-829.
30. Love S., et al. Neuronal death in brain infarcts in man. Neuropathol. Appl. Neurobiol. 26:2000;55-66.
31. Tatton N.A. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 166:2000;29-43.
32. Hartmann A., et al. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J. Neurosci. 21:2001;2247-2255.
33. Martin L.J. Neuronal death in amytrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J. Neuropathol. Exp. Neurol. 58:1999;459-471.
34. Shimohama S., et al. Changes in caspase expression in Alzheimer's disease: comparison with development and aging. Biochem. Biophys. Res. Commun. 256:1999;381-384.
35. Rohn T.T., et al. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol. Dis. 11:2002;341-354.
36. Zhao M., et al. The induction of the TNF-alpha death domain signaling pathway in Alzheimer's disease brain. Neurochem. Res. 28:2003;307-318.
37. Bilsland J., Harper S. Caspases and neuroprotection. Curr. Opin. Investig. Drugs. 3:2002;1745-1752.
38. Kang S.J., et al. Dissociation between neurodegeneration and caspase-11-mediated activation of caspase-1 and caspase-3 in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 23:2003;5455-5460.
39. Roy N., et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell. 80:1995;167-178.
40. Maier J.K., et al. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J. Neurosci. 22:2002;2035-2043.
41. Xu D.G., et al. Elevation of neuronal expression of NAIP reduces ischemic damage in the rat hippocampus. Nat. Med. 3:1997;997-1004.
42. Xu D., et al. Attenuation of ischemia-induced cellular and behavioral deficits by X chromosome-linked inhibitor of apoptosis protein overexpression in the rat hippocampus. J. Neurosci. 19:1999;5026-5033.
43. Rideout H.J., Stefanis L. Caspase inhibition: a potential therapeutic strategy in neurological diseases. Histol. Histopathol. 16:2001;895-908.
44. Mu X.J., et al. Altered expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord motor neurons. Ann. Neurol. 40:1996;379-386.
45. Ekegren T., et al. Upregulation of Bax protein and increased DNA degradation in ALS spinal cord motor neurons. Acta Neurol. Scand. 100:1999;317-321.
46. Hartmann A., et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J. Neurochem. 76:2001;1785-1793.
47. De La Monte S.M., et al. P53- and CD95-associated apoptosis in neurodegenerative diseases. Lab. Invest. 78:1998;401-411.
48. De La Monte S.M., et al. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J. Neurol. Sci. 152:1997;73-83.
49. Martin L.J. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol. Dis. 7:2000;613-622.
50. Tatton W., et al. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J. Neural Transm. 110:2003;509-515.
51. Zhu X., et al. Amyotrophic lateral sclerosis: a novel hypothesis involving a gained 'loss of function' in the JNK/SAPK pathway. Redox Rep. 8:2003;129-133.
52. Okazawa H., Estus S. The JNK/c-Jun cascade and Alzheimer's disease. Am. J. Alzheimers Dis. Other Demen. 17:2002;79-88.
53. Zhu X., et al. JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease. J. Neurochem. 85:2003;87-93.
54. Hartmann A., et al. FADD: A link between TNF family receptors and caspases in Parkinson's disease. Neurology. 58:2002;308-310.
55. Tatton W.G., et al. Maintaining mitochondrial membrane impermeability. An opportunity for new therapy in glaucoma? Surv. Ophthalmol. 45:(Suppl 3):2001;S277-S283.
56. Brunet A., et al. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 11:2001;297-305.
57. Wilson M.E., et al. Estradiol enhances Akt activation in cortical explant cultures following neuronal injury. Brain Res. Mol. Brain Res. 102:2002;48-54.
58. Concha N.O., Abdel-Meguid S.S. Controlling apoptosis by inhibition of caspases. Curr. Med. Chem. 9:2002;713-726.
59. Zhu S., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 417:2002;74-78.
60. Thomas M., et al. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin. Neuropharmacol. 26:2003;18-23.
61. Yang L., et al. Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res. 74:2003;278-285.
62. Duan W.Z., et al. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 52:2002;597-606.
63. Alves Da Costa C., et al. Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons. Proc. Natl. Acad. Sci. U. S. A. 99:2002;4043-4048.
64. Zhu X., et al. Novel p53 inactivators with neuroprotective action: syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7- hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7-hexahydrobenzoxazole derivatives. J. Med. Chem. 45:2002;5090-5097.
65. Sharpless N.E., Depinho R.A. p53: Good cop/bad cop. Cell. 110:2002;9-12.
66. Bassi L., et al. Pifithrin-alpha, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro. Mutat. Res. 499:2002;163-176.
67. Mucke H.A. CEP-1347 (Cephalon). Idrugs. 6:2003;377-383.
68. Chen R.W., et al. Involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and p53 in neuronal apoptosis: Evidence that GAPDH is upregulated by p53. J. Neurosci. 19:1999;9654-9662.
69. Kragten E., et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J. Biol. Chem. 273:1998;5821-5828.
70. Carlile G.W., et al. Reduced apoptosis after NGF and serum withdrawal: Conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a lycer. Mol. Pharmacol. 57:2000;2-12.
71. Tatton W.G., et al. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 301:2002;753-764.
72. Wadia J.S., et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: Time course and modification by (-)-deprenyl. J. Neurosci. 18:1998;932-947.
73. Youdim M.B., et al. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann. N. Y. Acad. Sci. 939:2001;450-458.
74. Berry M.D., Boulton A.A. Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases. Neurotoxicol. Teratol. 24:2002;667-673.
75. Kakimura J., et al. Release and aggregation of cytochrome c and α-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 417:2001;59-67.
76. Wheeler L., et al. Role of alpha-2 agonists in neuroprotection. Surv. Ophthalmol. 48:(Suppl 1):2003;S47-S51.
77. Maclusky N.J., et al. Ovarian steroids reduce apoptosis induced by trophic insufficiency in nerve growth factor-differentiated pc12 cells and axotomized rat facial motoneurons. Neuroscience. 118:2003;741-754.
78. Ahlskog J.E. Slowing Parkinson's disease progression - Recent dopamine agonist trials. Neurology. 60:2003;381-389.
79. Muller T. CPI-1189. Centaur. Curr. Opin. Investig. Drugs. 3:2002;1763-1767.
80. Clifford D.B., et al. Neurologic Aids Research Consortium: A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 59:2002;1568-1573.
81. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2:2003;566-580.
82. Blankenberg F.G., et al. Apoptotic cell death: its implications for imaging in the next millennium. Eur. J. Nucl. Med. 27:2000;359-367.
83. Karitzky J., Ludolph A.C. Imaging and neurochemical markers for diagnosis and disease progression in ALS. J. Neurol. Sci. 191:2001;35-41.
84. Ripova D., Strunecka A. An ideal biological marker of Alzheimer's disease: dream or reality? Physiol. Res. 50:2001;119-129.
85. Dib M., et al. Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease? J. Neurol. 249:2002;367-374.
86. Teunissen C.E., et al. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol. Aging. 23:2002;485-508.
87. Verbeek M.M., et al. Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases. Ann. Clin. Biochem. 40:2003;25-40.
88. Matthews B., et al. Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease. Am. J. Geriatr. Psychiatry. 11:2003;146-159.
89. Brooks D.J. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann. Neurol. 53:(Suppl 3):2003;S110-S118.
90. Waldmeier P.C., et al. Neurorescuing effects of the GAPDH ligand CGP 3466B. J. Neural Transm. Suppl. 60:2000;197-214.
91. Andringa G., et al. TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol. Dis. 14:2003;205-217.
92. Bunz F. Cell death and cancer therapy. Curr. Opin. Pharmacol. 1:2001;337-341.
93. Leifer B.P. Early diagnosis of Alzheimer's disease: clinical and economic benefits. J. Am. Geriatr. Soc. 51:2003;S281-S288.
94. Dekosky S.T. Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J. Am. Geriatr. Soc. 51:2003;S314-S320.